Frontier Biotechnologies Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 40.26 million compared to CNY 26.07 million a year ago. Revenue was CNY 42.44 million compared to CNY 26.17 million a year ago.

Net loss was CNY 173.08 million compared to CNY 123.26 million a year ago. Basic loss per share from continuing operations was CNY 0.46 compared to CNY 0.34 a year ago. Diluted loss per share from continuing operations was CNY 0.46 compared to CNY 0.34 a year ago.